Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV Infection

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of two combination chemotherapy regimens in treating patients with Hodgkin's disease and HIV infection.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centro di Riferimento Oncologico - Aviano
• Treatments: Bleomycin; Doxorubicin; Epirubicin; Etoposide; Liposomal doxorubicin; Mechlorethamine; Prednisone; Vinblastine; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Histologically proven Hodgkin's disease:

• Clinical or pathologic stage II - IV

• Stage I with bulky disease (tumor size greater than 10 cm) and B symptoms

• Confirmed HIV infection

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• WHO 0-4

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Not specified

Renal:

• Not specified

Cardiovascular:

• No severe cardiac disease

Pulmonary:

• No severe pulmonary disease

Other:

• No severe neurologic or metabolic disease

• No concurrent or prior second malignancy except:

• Nonmelanomatous skin cancer

• In situ cancer of the cervix

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• Not specified

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified

Other

• No prior therapy for Hodgkin's disease

• Concurrent triple-drug antiretroviral therapy (including one protease inhibitor) required